{"id":390023,"date":"2021-05-15T00:00:00","date_gmt":"2021-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0008-2021-biopharma-bladder-cancer-treatment-sequencing-us-2021\/"},"modified":"2026-03-31T10:43:15","modified_gmt":"2026-03-31T10:43:15","slug":"trsqon0008-2021-biopharma-bladder-cancer-treatment-sequencing-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0008-2021-biopharma-bladder-cancer-treatment-sequencing-us-2021\/","title":{"rendered":"Bladder Cancer | Treatment Sequencing | US | 2021"},"content":{"rendered":"<p><strong>KEY BENEFITS AND USES <\/strong><\/p>\n<ul>\n<li><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting.<\/li>\n<li><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand who\u00a0to position against or how to defend share.<\/li>\n<li><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design.<\/li>\n<li><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.<\/li>\n<li><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions.<\/li>\n<\/ul>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>Where is my product positioned versus competitors\u2019 products in the treatment journey?<\/li>\n<li>What are physicians\u2019 most frequent treatment sequences? Who is benefiting, and how can I defend my asset\u2019s share and position?<\/li>\n<li>What are the market-relevant treatment scenarios, according to oncology experts?<\/li>\n<li>Where are the untapped business opportunities on which I can capitalize on?<\/li>\n<li>How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Sequencing<\/em> provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.<\/p>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>PRIMARY MARKET RESEARCH <\/strong><\/p>\n<p>Survey of ~100 U.S. medical oncologists or urologists<\/p>\n","protected":false},"template":"","class_list":["post-390023","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390023\/revisions"}],"predecessor-version":[{"id":393148,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390023\/revisions\/393148"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}